COMPASS: Net clinical benefit of extended dual pathway inhibition according to Baseline risk in patients with chronic coronary syndrome: a COMPASS substudy
European Heart Journal-Cardiovascular Pharmacotherapy
Würtz M, Olesen KKW, Bhatt DL, Yusuf S, Muehlhofer E, Eikelboom JW, Maeng M.
March 2024
